Albert E Heacox Net Worth

The estimated Net Worth of Albert E Heacox is at least $2.23 millió dollars as of 15 August 2011. Albert Heacox owns over 15,450 units of Artivion Inc stock worth over $2,233,140 and over the last 21 years Albert sold CRY stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Albert Heacox CRY stock SEC Form 4 insiders trading

Albert has made over 3 trades of the Artivion Inc stock since 2007, according to the Form 4 filled with the SEC. Most recently Albert exercised 15,450 units of CRY stock worth $65,663 on 15 August 2011.

The largest trade Albert's ever made was exercising 19,880 units of Artivion Inc stock on 11 May 2007 worth over $43,736. On average, Albert trades about 1,550 units every 60 days since 2004. As of 15 August 2011 Albert still owns at least 124,896 units of Artivion Inc stock.

You can see the complete history of Albert Heacox stock trades at the bottom of the page.

What's Albert Heacox's mailing address?

Albert's mailing address filed with the SEC is CRYOLIFE, INC., 1655 ROBERTS BOULEVARD, N.W., KENNESAW, GA, 30144.

Insiders trading at Artivion Inc

Over the last 21 years, insiders at Artivion Inc have traded over $18,346,910 worth of Artivion Inc stock and bought 91,700 units worth $1,086,548 . The most active insiders traders include Steven G Anderson, Thomas F Ackerman és James P Mackin. On average, Artivion Inc executives and independent directors trade stock every 26 days with the average trade being worth of $211,842. The most recent stock trade was executed by Amy Horton on 8 December 2021, trading 2,500 units of CRY stock currently worth $46,425.

What does Artivion Inc do?

Headquartered in suburban Atlanta, Georgia, CryoLife is a leader in the manufacturing, processing, and distribution of medical devices and implantable tissues used in cardiac and vascular surgical procedures focused on aortic repair. CryoLife markets and sells products in more than 100 countries worldwide.

Complete history of Albert Heacox stock trades at Artivion Inc

Artivion Inc executives and stock owners

Artivion Inc executives and other stock owners filed with the SEC include:

• James Mackin,
  Chairman of the Board, President, Chief Executive Officer, Director
• D. Ashley Lee,
  Chief Financial Officer, Chief Operating Officer, Executive Vice President
• Jean Holloway,
  Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
• Michael Simpson,
  Senior Vice President - Regulatory Affairs and Quality Assurance
• John Davis,
  Senior Vice President - Global Sales and Marketing
• James Patrick Mackin,
  Chairman, Pres & CEO
• Scott Capps,
  Vice President - Clinical Research
• David Ashley Lee CPA, CPA,
  Exec. VP, COO & CFO
• Jean F. Holloway Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• John E. Davis,
  Sr. VP of Global Sales & Marketing
• Harvey Morgan,
  Independent Director
• Daniel Bevevino,
  Independent Director
• Ronald McCall,
  Presiding Independent Director
• Thomas Ackerman,
  Independent Director
• Jon Salveson,
  Independent Director
• James Bullock,
  Independent Director
• Jeffrey Burbank,
  Independent Director
• Marna Borgstrom,
  Independent Director
• Greg Chodaczek,
  IR Contact Officer
• Matthew Getz,
  Vice President - Human Resources
• Dennis Maier,
  Vice President - Operations
• Amy Horton,
  Chief Accounting Officer, Vice President
• Thomas Bogenschutz,
  Senior Vice President - EMEA, General Manager - Hechingen
• Dr. Marshall S. Stanton,
  Sr. VP of Clinical Research & Chief Medical Officer
• Joshua Wells,
  Sr. Director of Bus. Devel.
• Matthew A. Getz,
  VP of HR
• Amy D. Horton CPA, CPA,
  VP & Chief Accounting Officer
• Sherry M Saurini,
  VP, Quality
• C Elkins Ronald,
  Director
• James Benson,
  Director
• James M Mc Dermid,
  SVP, CHRO
• David C Gale,
  VP-Research and Development
• William Robert Matthews,
  Senior VP, Operations, Quality
• Thomas J Bogenschuetz,
  VP, EMEA & General Manager
• Bruce G. Anderson,
  VP, US Sales and Marketing
• Jeffrey W Burris,
  Vice President & Gen. Counsel
• Gerald B Seery,
  Sr. VP, Sales and Marketing
• John M Cook,
  Director
• David P. Lang,
  Sr. VP, Intl Sales & Marketing
• Steven G Anderson,
  President, CEO and Chairman
• Thomas J Lynch,
  VP - Reg. Aff./Quality Assur.
• Capital Management Oss,
  10% owner
• Philip A Theodore,
  VP, General Counsel
• Michaelstark Brian Jay Roth,
  
• Sidney B Ashmore,
  Vice President of Marketing
• Virginia C Lacy,
  Director
• Dyne Bruce J Md Van,
  Director
• Albert E Heacox,
  Sr. VP-Laboratory Operations
• Vander James C Wyk,
  VP - Product Integrity
• Kirby S Black,
  Sr. Vice President, R&D
• David Fronk,
  VP - Clinical Research
• Rochelle L. Maney,
  VP, Quality
• Franz Peter Barthold,
  VP, Research & Development
• Marshall S. Stanton,
  SVP, Clinical & MD Affair
• Anthony B. Semedo,
  Director